Gareth Gerrard

List of Publications by Year
in descending order

79 papers	2,772 citations	257450 24 h-index	175258 52 g-index
81 all docs	81 docs citations	81 times ranked	3654 citing authors

#	Article	IF	Citations
1	Assessment of *BCR-ABL1* Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2012, 30, 232-238.	1.6	449
2	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood, 2014, 123, 843-850.	1.4	321
3	Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature, 2010, 466, 765-768.	27.8	315
4	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 2011, 117, 3733-3736.	1.4	292
5	Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. British Journal of Haematology, 2010, 148, 80-89.	2.5	147
6	Guidelines for the measurement of *BCR‐ABL1* transcripts in chronic myeloid leukaemia. British Journal of Haematology, 2011, 153, 179-190.	2.5	94
7	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of *JAK2 V617F* and other relevant mutations. British Journal of Haematology, 2013, 160, 25-34.	2.5	87
8	Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood, 2013, 121, 2739-2742.	1.4	85
9	A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR. Leukemia, 2015, 29, 369-376.	7.2	72
10	Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood, 2012, 119, 1838-1843.	1.4	68
11	Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica, 2004, 89, 782-90.	3.5	66
12	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 2002, 117, 427-435.	2.5	65
13	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph‰+‰ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia, 2019, 33, 1910-1922.	7.2	54
14	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia, 2016, 30, 1844-1852.	7.2	51
15	*BCR‐ABL1* kinase domain mutations: Methodology and clinical evaluation. American Journal of Hematology, 2012, 87, 298-304.	4.1	50
16	Target enrichment and high‐throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond‐Blackfan anaemia. British Journal of Haematology, 2013, 162, 530-536.	2.5	50
17	hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia, 2010, 24, 1243-1245.	7.2	43
18	Technical aspects and clinical applications of measuring *BCR‐ABL1* transcripts number in chronic myeloid leukemia. American Journal of Hematology, 2009, 84, 517-522.	4.1	40

#	Article	IF	Citations
19	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica, 2019, 104, 2400-2409.	3.5	37
20	Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients. Journal of Molecular Diagnostics, 2016, 18, 176-189.	2.8	34
21	A common novel splice variant of *SLC22A1* (*OCT1*) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. British Journal of Haematology, 2013, 163, 631-639.	2.5	33
22	Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs. Blood, 2015, 125, 2553-2557.	1.4	33
23	Cytogenetics of multiple myeloma: interpretation of fluorescence *in situ* hybridization results. British Journal of Haematology, 2003, 120, 944-952.	2.5	32
24	EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood, 2010, 116, 6014-6017.	1.4	29
25	Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. Leukemia, 2008, 22, 1806-1807.	7.2	23
26	Stability of Conversion Factors for BCR-ABL Monitoring -â€" Implications for the Frequency of Validation Rounds. Blood, 2010, 116, 893-893.	1.4	16
27	Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: Innovation, automation, and harmonization. American Journal of Hematology, 2012, 87, 717-720.	4.1	14
28	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3081-3089.	2.5	14
29	The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. Haematologica, 2009, 94, 861-864.	3.5	12
30	Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. European Journal of Pharmacology, 2009, 609, 34-39.	3.5	12
31	Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood, 2012, 120, 697-698.	1.4	12
32	*PTCH1* expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. American Journal of Hematology, 2015, 90, 20-26.	4.1	11
33	Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples. Journal of Clinical Pathology, 2022, 75, 241-249.	2.0	11
34	Duplex quantitative PCR for molecular monitoring of *BCRâ€ABL1*â€associated hematological malignancies. American Journal of Hematology, 2011, 86, 313-315.	4.1	10
35	Analysis of BCRâ€"ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. Leukemia, 2010, 24, 1817-1821.	7.2	9
36	Targeted next generation sequencing of pancreatic solid pseudopapillary neoplasms show mutations in Wnt signaling pathway genes. Pathology International, 2019, 69, 193-201.	1.3	8

#	Article	IF	Citations
37	Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia. Oncotarget, 2016, 7, 65923-65936.	1.8	8
38	Assessment of quantitative polymerase chain reaction for <i>BCRâ€"ABL1</i> transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact ofÂtechnology?. British Journal of Haematology, 2022, 197, 52-62.	2.5	7
39	The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for â€˜Stopping' Studies. Blood, 2011, 118, 605-605.	1.4	6
40	Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?. Oncotarget, 2019, 10, 696-706.	1.8	6
41	Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,. Blood, 2011, 118, 3777-3777.	1.4	5
42	Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia. Leukemia Research, 2016, 49, 47-50.	0.8	4
43	Real-time Quantification Assay to Monitor BCR-ABL1 Transcripts in Chronic Myeloid Leukemia. Methods in Molecular Biology, 2014, 1160, 115-124.	0.9	4
44	Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration. Blood, 2016, 128, 1918-1918.	1.4	4
45	Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.. Blood, 2005, 106, 1466-1466.	1.4	4
46	Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. British Journal of Haematology, 2014, 164, 608-610.	2.5	3
47	Molecular and Cytogenetic Analysis. , 2017, , 126-164.		3
48	Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. Blood, 2011, 118, 1680-1680.	1.4	3
49	NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA. Blood, 2013, 122, 4006-4006.	1.4	3
50	Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent. Blood, 2013, 122, 93-93.	1.4	2
51	Incidence of Vascular Thrombotic Events in 183 Consecutive Patients Treated with Nilotinib: A Single Centre Experience. Blood, 2014, 124, 3147-3147.	1.4	2
52	Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy. Blood, 2016, 128, 1223-1223.	1.4	2
53	Pushing the boundaries of in situ hybridisation for mRNA demonstration: demonstration of kappa and lambda light chain restriction in follicular lymphoma. British Journal of Biomedical Science, 2019, 76, 143-146.	1.3	1
54	Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatmentâ€"a Subanalysis of the ENEST1st Study. Blood, 2014, 124, 3144-3144.	1.4	1

#	Article	IF	Citations
55	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. Blood, 2010, 116, 894-894.	1.4	1
56	Targeted Sequencing of Sorted Peripheral Blood Cells Reveals Novel Germline and Somatic Variants in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis. Blood, 2015, 126, 5213-5213.	1.4	1
57	Alternative tissue fixation for combined histopathological and molecular analysis in a clinically representative setting. Histochemistry and Cell Biology, 2021, 156, 595-607.	1.7	1
58	Glucosylceramide Synthetase Inhibitors Sensitise B-CLL Cells to Cytotoxic Agents without Reversing P-gp Functional Activity.. Blood, 2004, 104, 1181-1181.	1.4	0
59	Sequential Quantitative Minimal Residual Disease in BCR-ABL Positive Acute Lymphoblastic Leukaemia: Differential Observations between Major and Minor Fusion Gene Rearrangements and Variation Due to Source Material.. Blood, 2004, 104, 1093-1093.	1.4	0
60	Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia. Blood, 2008, 112, 3113-3113.	1.4	0
61	WT1 and PRAME Expression in CML: Quantitation by Real-Time PCR and Correlation with BCR-ABL Expression Levels. Blood, 2008, 112, 4225-4225.	1.4	0
62	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.. Blood, 2009, 114, 3248-3248.	1.4	0
63	Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.. Blood, 2010, 116, 3397-3397.	1.4	0
64	PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients. Blood, 2012, 120, 875-875.	1.4	0
65	Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?. Blood, 2012, 120, 68-68.	1.4	0
66	Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?. Blood, 2012, 120, 3760-3760.	1.4	0
67	Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.. Blood, 2012, 120, 2789-2789.	1.4	0
68	A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. Blood, 2012, 120, 2555-2555.	1.4	0
69	Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.. Blood, 2012, 120, 2369-2369.	1.4	0
70	Targeted High-Throughput Sequencing For The Detection Of Mutations Associated With Myeloproliferative Neoplasms. Blood, 2013, 122, 1613-1613.	1.4	0
71	The Depth Of â€˜Completeâ€™ Molecular Response Predicts Molecular Relapse In Chronic Myeloid Leukaemia Patients On Tyrosine Kinase Inhibitor Therapy. Blood, 2013, 122, 5201-5201.	1.4	0
72	Clinical Outcome Following Change of Tyrosine Kinase Inhibitor (TKI) According to the Detection of an ABL Kinase Mutation. Blood, 2014, 124, 4557-4557.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML). Blood, 2015, 126, 2794-2794.	1.4	0
74	DNA Methylation Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis. Blood, 2015, 126, 5204-5204.	1.4	0
75	Gene Expression Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Polycythemia Vera and Primary Myelofibrosis. Blood, 2015, 126, 5201-5201.	1.4	0
76	Differential Expression of Genes Associated with Oncogene-Induced Senescence and Senescence Associated Secretory Phenotype in the Absence of Differential Expression of High Molecular Risk Genes and Genes Associated with JAK-STAT Pathway in Sorted Cells of Patients with Polycythemia Vera and Primary Myelofibrosis. Blood, 2016, 128, 4283-4283.	1.4	0
77	Germline Calr exon 9 Variant and Somatic JAK2 V617F Mutation in a Patient with Polycythemia Vera Associated with Late Presentation and Severe Clinical Phenotype. Blood, 2016, 128, 5485-5485.	1.4	0
78	DNA-Based Digital PCR for the Quantification of Residual Disease in CML â€" Sensitivity or Specificity?. Blood, 2018, 132, 1738-1738.	1.4	0
79	Verteporfin Photodynamic therapy with 5 aza-deoxy-cytidine for neo-adjuvant treatment of primary breast cancer: Results of pre-clinical investigations. , 2019, , .		0